Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Melanoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Flow Cytometry 3Cyclophosphamide 3Radiotherapy 2Methylprednisolone 2Interviews as Topic 2Immunologic Techniques 2Alemtuzumab 2sargramostim 1saracatinib 1resiquimod 1poly ICLC 1orantinib 1motexafin gadolinium 1liposomal doxorubicin 1fludarabine phosphate 1flt3 ligand protein 1dexamethasone acetate 1dexamethasone 21-phosphate 1cediranib 1aldesleukin 1Thrombopoietin 1Thiotepa 1Therapeutics 1Tacrolimus 1Surveys and Questionnaires 1Stem Cell Factor 1Psychiatric Rehabilitation 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × resiquimod × Breast × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡